药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Geranylgeranyl diphosphate
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Farnesyl diphosphate
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Triptorelin
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Histrelin
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Buserelin
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Degarelix
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Pasireotide
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Cariporide
The risk or severity of QTc prolongation can be increased when Cariporide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Amisulpride
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Tandutinib
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Methsuximide
The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Farnesyl thiopyrophosphate
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Fleroxacin
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Vorinostat
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Penfluridol
The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Lorcainide
The risk or severity of QTc prolongation can be increased when Lorcainide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Bunaftine
The risk or severity of QTc prolongation can be increased when Bunaftine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Nizofenone
The risk or severity of QTc prolongation can be increased when Nizofenone is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Otilonium
The risk or severity of QTc prolongation can be increased when Otilonium is combined with Berotralstat.